Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ocera Therapeutics Inc.

This article was originally published in Start Up

Executive Summary

The founders of Ocera Therapeutics recognize that the medical needs of patients with gastrointestinal and liver diseases are largely unmet, and they think they can do something about it. Their goal is to develop new therapeutic products for inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and liver disease sufferers by in-licensing clinical-stage compounds with promising efficacy and safety profiles.

You may also be interested in...



Signs of Movement in IBS Drug Development

Despite Big Pharma's struggles, the availability of compounds developed for other pain indications could energize start-ups' interest in irritable bowel syndrome.

Biodesy LLC

Second-harmonic generation is an optical phenomenon that occurs when a nonlinear surface combines photons of light to produce photons with twice the frequency and half the wavelength of the original photons. Biodesy is harnessing its power to measure protein conformation for drug discovery.

Jenken Biosciences Inc.

At present, there are no approved small molecule anti-inflammatory drugs for treating hepatitis C. Indeed, most drug R&D activity for hepatitis centers on new or improved anti-viral therapy rather than complications of the infection, e.g., the chronic inflammation that occurs in 80% of hepatitis cases. Jenken Biosciences hopes to change that. Jenken is repurposing two different, chemically similar, marketed compounds for new indications associated with chronic organ inflammation.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091214

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel